Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S Smolen, Robert Landewé, Sytske Anne Bergstra et al. · Annals of the Rheumatic Diseases · 2022 · 1.8K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls et al. · New England Journal of Medicine · 2022 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A Bayesian neural network method for adverse drug reaction signal generation

Andrew Bate, Marie Lindquist, I. Ralph Edwards et al. · European Journal of Clinical Pharmacology · 1998 · 1.4K citations

Pharmacy, Pharmacology, Toxicology +14

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Joe‐Elie Salem, Ali Manouchehri, Melissa Moey et al. · The Lancet Oncology · 2018 · 1.2K citations

Life Sciences, Immunology, Pharmacology +16

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Roy Fleischmann, Joel M. Kremer, John J. Cush et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12